Type 1 Diabetes Drug Effective In Stopping Beta Cell Destruction

An experimental drug that has been studied for nearly 20 years continues to show effectiveness in about half of the patients who participated in a recent phase 2 clinical trial. The drug, Teplizumab -- also known as anti CD3 -- is designed to block the advance of Type 1 Diabetes in its earliest stages. 

Recently published in the journal Diabetes, this promising research continues to be spear-headed by former Diabetes Center Director and current Executive Vice Chancellor and Provost, Jeffrey Bluestone, PhD.  Click here to read the article.